Response rate accuracy in oncology;Fiabilité des taux de réponses en oncologie: Analyse des causes de variation

Bulletin du Cancer

Volumn 87, Issue 12, 2000, Pages 927-934

  Negrier S ^a   Ollivier, L ^a   Di Stefano Louineau, D ^a   Escudier, B ^a   Savary, J ^a   Lasset, C ^a   Thiesse, P ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Clinical trial; Evaluation; Response rate; Tumor response

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; HEALTH CARE QUALITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEASUREMENT; MEDICAL AUDIT; METHODOLOGY; MULTICENTER STUDY; OUTCOMES RESEARCH; PEER REVIEW; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MULTICENTER STUDIES; NEOPLASMS; PROFESSIONAL STAFF COMMITTEES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0034507728     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Reporting results of cancer treatment
2. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials
3. Tumor response in comparative trials
4. How reliable are tumor measurements?
5. Assessment of response to therapy in advanced breast cancer
6. What does «response» in cancer chemotherapy really mean?
7. Reflections on medical oncology: An appeal for better clinical trials and improved reporting of their results
8. Comparisons of cooperative group evaluation criteria for multiple drug therapy for breast cancer
9. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies
10. Recombinant interferon α-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study
11. Interferon alfa-2 in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long term follow-up
12. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: Report of a European multicenter study
13. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-actived killer cells and interleukln-2 or high-dose interleukin-2 alone
14. Measuring masses on cross-sectional images
15. Quantification of tumor response to anti-neoplasic therapy
16. Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response
17. Care for using only maximum diameter in measuring rumors
18. Response rate accuracy in oncology trials: Reasons for interobserver variability
19. Hypervascular hepatic metastases: CT evaluation
20. Detection of hepatic metastase in breast cancer: The role of non enhanced and enhanced CT scanning
21. Helical biphasic contrast-enhanced CT of the liver: Technique, indications, interpretation and pitfalls
22. Biology and therapy for good, intermediate and selected poor prognosis neuroblastoma
23. Conventional dose chemotherapy vs ablative chemotherapy with autologous bone marrow transplantation for high risk neuroblastoma
24. Three-dimensional quantitation of pediatric tumor bulk
25. The clinical measurement of volumes using helical CT
26. Influence of clinical history upon detection of nodules and other lesions
27. Interpretation of radiographs: Effect of clinical history
28. Paired receiver operating characteristic curves and the effect of history on radiographic interpretation: CT of the head as a case study
29. Analysis of interobserver and intraobserver variability in CT tumor measurements
30. Inadequacy of ultrasonography for monitoring response to treatment of liver metastases
31. Measuring response in solid tumors: Unidimensional versus bidimensional measurement
32. New guidelines to evaluate the response to treatment in solid tumors
33. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma